Aim: A novel device has been developed for measuring the cardio-ankle vascular index (CAVI) as an indicator of arterial stiffness. In this study, we evaluated the effect of pitavastatin on CAVI in type 2 diabetic patients. Methods: Forty-five type 2 diabetes mellitus patients with low-density lipoprotein cholesterolemia were enrolled and treated with pitavastatin 2 mg/day for 12 months. Before and after pitavastatin administration, HbA1c, serum lipids, serum malondialdehyde-LDL (MDA-LDL), urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG) and CAVI were measured. 
Introduction
Diabetic patients complicated with high low-density lipoprotein cholesterol (LDL-C) are at increased risk of macroangiopathy 1, 2) ; therefore, in diabetic patients, intensive LDL-C-lowering therapy is needed to prevent the progression of atherosclerosis. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are known to be effective in lowering LDL-C. Among the statins, pitavastatin has a potent LDL-Clowering effect. Various studies have reported significant decreases in the frequency of coronary heart disease by statin therapy [3] [4] [5] . Thus, the main purpose of Recently, a novel arterial stiffness parameter, termed cardio-ankle vascular index (CAVI), has been developed, which essentially reflects the stiffness of the aorta, femoral artery and tibial artery 12) . CAVI is independent of blood pressure, and has adequate reproducibility for clinical use 12) . Furthermore, no special technique is required to measure CAVI. Several reports have demonstrated the usefulness of CAVI to detect atherosclerotic diseases [12] [13] [14] [15] .
In the present study, we evaluated the effect of pitavastatin on CAVI in type 2 diabetic patients with high LDL-C.
Subjects and Methods

Subjects
A randomized, open study was performed. Fortyfive type 2 diabetes mellitus patients with high LDL-C, who attended Sakura Medical Center of Toho University as outpatients, were enrolled. Patients were excluded if they had received insulin therapy, or had diabetic retinopathy, nephropathy or previous cardiovascular and cerebrovascular diseases. The enrolled subjects were treated with pitavastatin 2 mg/day for 12 months. The clinical profile of the subjects is shown in Table 1 . During the study period, all patients maintained the same diet and exercise therapies, and did not change medications. All subjects received nutrition education from a dietitian every month. This study was approved by the institutional review board. The purpose of this study was explained to the subjects, and consent was obtained for participation in the study and also for release of the study data.
Measurement of Body Weight and Blood Pressure
Body weight and blood pressure were measured in the morning after 12 hours of fasting. Blood pressure was measured at least twice in a sitting position.
Assay of HbA1c and Serum Lipids
Blood samples were collected in the morning after 12 hours of fasting. Serum was separated within 1 hour, and samples were used to measure the following chemical parameters. Stable and unstable fractions of glycosylated hemoglobin (HbA1c) were measured by high pressure liquid chromatography using the HiAuto A1c kit (Kyoto Daiichi Kagaku, Kyoto, Japan). Data of the stable type were used in the present analysis. Total cholesterol (TC), triglyceride (TG) and LDL-C were measured with an automatic analyzer (Hitachi 7150; Hitachi Tokyo, Japan). High-density lipoprotein cholesterol (HDL-C) was measured by the selective inhibition method (Daiichi Pure Chemicals, Tokyo) 16) .
Assay of Serum Malondialdehyde-LDL
Serum malondialdehyde-LDL (MDA-LDL) was assayed by ELISA as described previously 17) . Monoclonal antibodies against MDA-LDL (ML25) and apo B (AB16) were used. These antibodies and 2 − 15% nondenaturing polyacrylamide gels were obtained from Daiichi Chemicals Co. (Tokyo, Japan).
Urinary 8-OHdG Analysis
Urine samples were centrifuged at 800 g for 10 min and the supernatant was used to determine 8-hydroxy-2'-deoxyguanosine (8-OHdG) by a competitive enzyme-linked immunosorbent assay (8-Hydroxydeoxyguanosine Check; Japan Institute for the Control of Aging, Shizuoka, Japan). The monoclonal antibody has been characterized and found to be specific for 8-OHdG 18) . The results were adjusted for creatinine (per mg Cr) measured in the same urine sample.
Measurement of CAVI
CAVI was measured using a VaSera CAVI instrument (Fukuda Denshi Co. Ltd., Tokyo) by the meth- . CAVI was measured in the morning after 12 hours of fasting. Briefly, cuffs were applied to bilateral upper arms and ankles, with the subject supine and the head held in the midline position. Examinations were performed after resting for 10 minutes. To detect brachial and ankle pulse waves with cuffs, a low cuff pressure of 30 to 50 mmHg was used to ensure the minimal effect of cuff pressure on hemodynamics. Blood pressure was measured thereafter. CAVI was calculated by the following formula:
where Ps is systolic blood pressure, Pd is diastolic blood pressure, PWV is pulse wave velocity, P is Ps Pd, is blood density, and a and b are constants.
Scale conversion was performed to compare CAVI with PWV (Hasegawa's method). The VaSera was equipped with both measurement and calculation systems, and automatically calculated CAVI. The average coefficient of variation of CAVI is less than 5%, which is sufficiently low for clinical usage and indicates that CAVI has good reproducibility 12) .
Statistical Analysis
Comparison between groups was performed using Student's t -test or the paired t -test. The relationship between changes in CAVI and each parameter was analyzed using simple regression analysis. In all comparisons, p 0.05 was considered significant.
Results
Changes in Clinical Parameters After Pitavastatin Treatment
The changes in clinical parameters after pitavastatin treatment are shown in Table 1 . After pitavastatin administration for 12 months, significant decreases in TC and LDL-C and a significant increase in HDL-C were observed. No significant changes in body weight, BMI, blood pressure, HbA1c and TG were observed.
Changes in 8-OHdG and MDA-LDL After 12 Months of Pitavastatin Treatment
The changes in urinary 8-OHdG and serum MDA-LDL are shown in Fig. 1 . After pitavastatin treatment for 12 months, significant decreases in 8-OHdG from 11.3 to 8.4 ng/mg Cr (p 0.05) and MDA-LDL from 170 to 114 U/L (p 0.01) were observed.
Change in CAVI After 12 Months of Pitavastatin Treatment
The changes in CAVI are shown in Fig. 2 . A significant decrease in CAVI from 9.54 to 8.91 (p 0.05) was observed after 12 months of pitavastatin treatment.
Correlation between Change in CAVI and Changes in Other Parameters
Simple regression analyses were performed to Comparison of Background between CAVIImproved Group (Responders) and -Nonimproved Group (Non-Responders) Subjects were divided into two groups: a group with improved CAVI ( CAVI 0; responders, n 32) and a group with no improvement in CAVI ( CAVI 0; non-responders, n 13). The baseline clinical profile of two groups and the changes in clinical parameters are shown in Table 3 . Baseline levels of HbA1c, 8-OHdG and CAVI in responders were significantly higher than in non-responders. TC and LDL-C fell significantly in both responders and non-responders; however, the changes in TC and LDL-C were not significantly different between groups (Table 3) . Decreases in 8-OHdG and MDA-LDL were greater in responders than in non-responders, and the change in MDA-LDL was significantly different between groups (Table 3) .
Discussion
A novel arterial stiffness indicator, termed CAVI, has been developed recently as a noninvasive and easy technique for the diagnosis of atherosclerosis [12] [13] [14] [15] . In this study, we demonstrated that pitavastatin was effective in reducing 8-OHdG, MDA-LDL and CAVI in type 2 diabetes patients with high LDL-C, and that the change in CAVI correlated with the change in MDA-LDL. These results suggested that pitavastatin has the potential to reduce oxidative stress and may improve arterial stiffness by this potential.
In the diabetic state, increased production of reactive oxygen species and decreased antioxidant capacity have been observed, both resulting in increased oxidative stress [19] [20] [21] . Enhanced oxidative stress may be closely related to the pathogenesis of atherosclerosis 19, 21, 22) . In the present study, pitavastatin significantly decreased 8-OHdG, which is known to be a useful indicator of systemic oxidative stress 23, 24) . Pitavastatin has been reported to decrease vascular reactive oxygen (ROS) and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity 25, 26) . These effects of pitavastatin may be reflected by a decrease in 8-OHdG. Furthermore, increased oxidative stress and high levels of LDL may accelerate the production of oxidized LDL. The present results suggest that pitavastatin may decrease MDA-LDL, which is known to be a form of oxidized LDL 27, 28) , by two major mechanisms: a systemic oxidative stress-ameliorating effect and a LDL-C-lowering effect.
There are at least two possible explanations for the mechanisms of CAVI reduction. The first is regression of a vascular organic lesion. Recent reports indicate that CAVI is capable of detecting the presence of a vascular organic lesion [12] [13] [14] [15] , which might regress as a result of reduced oxidative stress. For example, Tani et al. 29) demonstrated the regression of coronary atherosclerosis by reducing MDA-LDL by 12.7%. Ono et al. 30) reported that carotid intima-media thickness was decreased by reducing 8-OHdG from 10.98 to 7.61 ng/mg Cr. In the present study, the magnitudes of decrease in MDA-LDL (33%) and 8-OHdG (11.3 to 8.4 ng/mg Cr) were comparable or better than in pre- vious studies. Thus, the reduction of CAVI observed in this study may well reflect the improvement of a vascular organic lesion as a result of significant decreases in MDL-LDL and 8-OHdG. Another possible mechanism is improved endothelial function. Among mega trials with statins, the ASTEROID trial (A Study To evaluate the Effect of Rosuvastatin On Intravascular ultrasound-Derived coronary atheroma burden) demonstrated that a decrease in LDL-C to 60.8 mg/dL by very high-intensity statin therapy resulted in a significant reduction of plaque volume in patients with coronary heart disease confirmed by coronary angiography 31) . In the present study, the reduction of LDL-C did not reach the level achieved in the ASTEROID trial. Furthermore, our study duration was 12 months compared with 2 years in ASTEROID. Thus, from the viewpoint of the LDL-C-reducing effect, pitavastatin treatment for 12 months is unlikely to have regressed atherosclerotic lesions in our patients. It has been reported that oxidized LDL and 8-OHdG contribute to atherogenetic processes by inducing vascular endothelial dysfunction 32, 33) . Therefore, the improvement in CAVI observed in our study may be consistent mainly with the improvement of endothelial dysfunction but not the regression of a organic lesion. Endothelial function is known to be affected by many factors, especially by dietary conditions 34, 35) ; therefore, further studies to clarify the effects of these factors are required in the future.
In this study, the patients were divided into two groups: one group showed improved CAVI (responders), and the other group showed no improvement in CAVI (non-responders). The responders showed a significantly greater decrease in MDA-LDL than nonresponders, although the decreases in LDL-C were almost identical in the two groups. To clarify the characteristics of responders and non-responders, we compared the baseline data of the two groups. Serum HbA1c, urinary 8-OHdG and the CAVI were significantly higher in responders than in non-responders. These findings suggest that the potential of pitavastatin to ameliorate oxidative stress may be enhanced in a state of deteriorated metabolic disorder, and this potential may be independent of the lipid-lowering action. CAVI is known to correlate positively with age and has different normal values in males and females 12) . In the present study, age and the male/female ratio were not significant difference in responder and non- responder groups; therefore, these factors were considered to have had no effect on the results. Diabetes mellitus is a very important risk factor for atherosclerosis. Atherosclerotic diseases are a common cause of sudden death, partially due to the lack of a simple and reliable noninvasive diagnostic method of atherosclerosis that can be used routinely in clinical settings. In the present study, CAVI was improved by pitavastatin treatment accompanied by a reduction of oxidative stress. From these findings, we conclude that pitavastatin may be effective to improve arterial stiffness in patients with enhanced oxidative stress, and that CAVI may be useful as a routine test for the diagnosis and therapeutic monitoring of atherosclerosis. A large-scale prospective study to evaluate CAVI and the effectiveness of intensive statin therapy is warranted.
